Nanexa AB — Investor Relations & Filings

Nanexa AB is a pharmaceutical development company specializing in Long-Acting Injectables (LAIs). The company's core is its proprietary drug delivery system, PharmaShell®, a nanotechnology platform that utilizes Atomic Layer Deposition (ALD) to coat drug particles. This technology enables the precise and controlled long-term release of medications, facilitating the development of a new generation of drug products, including 'super generics'. Nanexa's focus is on creating injectable treatments with less frequent administration, such as monthly injections, for therapeutic areas including type 2 diabetes, obesity, cancers, and psychiatric disorders.